Gabather, Receives Notice of Approval from the Japanese Patent Office (JPO) for its National Phase Application No. 2020-554957
Gabather AB (Nasdaq First North Growth Market: GABA), a clinical stage pharmaceutical company developing novel therapeutics for neuropsychiatric disorders, is pleased to announce that it has received approval from the JPO for the national phase patent application No. 2020-554957.The invention relates to the synthesis and production of triazoloquinazolinones and is based on the PCT International Application No. PCT/IB2018/001573. The invention expands our position in the field of GABA\A\ receptor modulators and medical use. This patent together with our patent portfolio covers key products